2026 Thomas J. Kipps: Immunology Researcher – H-Index, Publications & Awards

Discipline name	D-Index	World Ranking	Current World Ranking	National Ranking	Current National Ranking	Publications	Citations
Immunology	140	161	149	108	99	927	97245
Medicine	141	1590	1472	928	850	943	97651

Research.com Recognitions

2026 - Research.com Immunology in United States Leader Award
2025 - Research.com Immunology in United States Leader Award
Member of the Association of American Physicians
Member of the Association of American Physicians
Member of the Association of American Physicians
Member of the Association of American Physicians

Overview

Thomas J. Kipps is an active researcher affiliated with the University of California, San Diego in the United States. Their work primarily focuses on the field of Medicine with significant contributions to Genetics, Pathology and Forensic Medicine, Immunology, Molecular Biology, and Oncology.

The researcher has published extensively on several topics related to hematologic malignancies and immune disorders. Major research themes include:

Chronic Lymphocytic Leukemia Research
Lymphoma Diagnosis and Treatment
Immunodeficiency and Autoimmune Disorders
Chronic Myeloid Leukemia Treatments
Acute Lymphoblastic Leukemia Research
Galectins and Cancer Biology
CAR-T Cell Therapy Research

Thomas J. Kipps has contributed to key journals in the medical research landscape. Frequent publication venues in their record include:

Blood
Journal of Clinical Oncology
Cancer Research
Clinical Lymphoma Myeloma & Leukemia
Leukemia

Their coauthors often include names such as Laura Z. Rassenti, William G. Wierda, Tanya Siddiqi, Paolo Ghia, and Alessandra Tedeschi, indicating collaboration with established researchers in related fields.

Among their recent papers are the following publications:

Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial, 2020, The Lancet Oncology
Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia, 2022, Blood Advances
Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study, 2021, Journal of Clinical Oncology
Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study, 2020, Journal of Clinical Oncology
Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort, 2022, Blood

Thomas J. Kipps holds the distinction of being a member of the Association of American Physicians, reflecting recognition within the medical research community.

Best Publications

Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia

George Adrian Calin;Calin Dan Dumitru;Masayoshi Shimizu;Roberta Bichi

7070
Citations
miR-15 and miR-16 induce apoptosis by targeting BCL2.

Amelia Cimmino;George Adrian Calin;Muller Fabbri;Marilena V. Iorio

4884
Citations
Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelines

Michael Hallek;Bruce D. Cheson;Daniel Catovsky;Federico Caligaris-Cappio

4504
Citations
A MicroRNA Signature Associated with Prognosis and Progression in Chronic Lymphocytic Leukemia

George Adrian Calin;Manuela Ferracin;Manuela Ferracin;Amelia Cimmino;Gianpiero Di Leva

3152
Citations
Idelalisib and rituximab in relapsed chronic lymphocytic leukemia.

Richard R. Furman;Jeff P. Sharman;Steven E. Coutre;Bruce D. Cheson

2154
Citations
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia

Andrew W. Roberts;Matthew S. Davids;John M. Pagel;Brad S. Kahl

2109
Citations
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.

J. C. Byrd;J. R. Brown;Susan O'Brien;J. C. Barrientos

1961
Citations
MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias

George Adrian Calin;Chang Gong Liu;Cinzia Sevignani;Manuela Ferracin

1793
Citations
Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia

Jan A. Burger;Alessandra Tedeschi;Paul M. Barr;Tadeusz Robak

1780
Citations
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL

Michael Hallek;Bruce D. Cheson;Daniel Catovsky;Federico Caligaris-Cappio

1735
Citations
CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment.

Jan A. Burger;Thomas J. Kipps;Thomas J. Kipps

1487
Citations
Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia.

Andreas Rosenwald;Ash A. Alizadeh;George Widhopf;Richard Simon

1415
Citations
ZAP-70 Compared with Immunoglobulin Heavy-Chain Gene Mutation Status as a Predictor of Disease Progression in Chronic Lymphocytic Leukemia

Laura Z. Rassenti;Lang Huynh;Tracy L. Toy;Liguang Chen

1202
Citations
Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors.

Franco Fais;Fabio Ghiotto;Shiori Hashimoto;Brian Sellars

1099
Citations
MiR-15a and miR-16-1 cluster functions in human leukemia.

George A. Calin;Amelia Cimmino;Muller Fabbri;Manuela Ferracin

1007
Citations
Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia

John F. Seymour;Thomas J. Kipps;Barbara Eichhorst;Peter Hillmen

979
Citations
Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1.

Jan A. Burger;Nobuhiro Tsukada;Meike Burger;Nathan J. Zvaifler

970
Citations
Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease

Andrew W. Roberts;John F. Seymour;John F. Seymour;Jennifer R. Brown;William G. Wierda

946
Citations
Ultraconserved Regions Encoding ncRNAs Are Altered in Human Leukemias and Carcinomas

George A. Calin;Chang gong Liu;Manuela Ferracin;Terry Hyslop

920
Citations
Clinical Utility of Microarray-Based Gene Expression Profiling in the Diagnosis and Subclassification of Leukemia: Report From the International Microarray Innovations in Leukemia Study Group

Torsten Haferlach;Alexander Kohlmann;Lothar Wieczorek;Giuseppe Basso

886
Citations

Frequent Co-Authors

Laura Z. Rassenti University of California, San Diego

William G. Wierda The University of Texas MD Anderson Cancer Center

John C. Byrd University of Pittsburgh Cancer Institute

Jennifer R. Brown Harvard University

Susan O'Brien University of California, Irvine

Peter Hillmen St James's University Hospital

Steven Coutre Stanford University

Jan A. Burger The University of Texas MD Anderson Cancer Center

Dennis A. Carson University of California, San Diego

Carlo M. Croce The Ohio State University

External Links

Personal website of Thomas J. Kipps

If you think any of the details on this page are incorrect, let us know.

Related Online Degrees & Career Pathways

For those interested in immunology, pursuing related healthcare degrees online can open various career pathways. One growing field is psychiatric mental health nursing, where specialized programs offer strong clinical experience. Exploring the best psychiatric mental health nurse practitioner programs online can help students find top-quality education with excellent hands-on training.

Cost is also a significant consideration. Students seeking budget-friendly options should consider the cheapest online pmhnp programs, which provide a valuable balance between affordability and comprehensive course content. This is particularly relevant given the investment required for advanced degrees.

Understanding earning potential is essential for career planning. Those pursuing a Doctor of Nursing Practice may want to review data on how much does a dnp make across different states to evaluate the financial viability of their goals.

Additionally, for family nurse practitioners aiming to specialize further, the option to transition is available. Programs like the fnp to acnp bridge program online enable nurses to expand their expertise into acute care, broadening their career opportunities in healthcare fields linked to immunology.